Bachmann C
Laboratoire Central de Chimie Clinique, Université de Lausanne, CHUV, Switzerland.
Acta Gastroenterol Belg. 2005 Oct-Dec;68(4):466-8.
Evaluation of long-term outcome of patients with urea cycle diseases (UCD) is needed for medical decisions and counselling. Own data comparing outcome of UCD patients with the old treatment limited to protein restriction (i.e. close to the natural history) with that of patients on the modern conservative treatment have shown that gains in survival occur at the cost of more mentally retarded surviving patients. We discuss the possible bias in long-term outcome studies of those rare inheritable disorders where non-predictable environmental factors leading to catabolic crises have a crucial impact on prognosis. A combination of peak or initial ammonia value combined with the duration of coma is discussed as a criterion for prognosis of handicap. The neglect of dietary compensation of branched chain amino acid deficiency worsened by phenylbutyrate treatment in some published protocols could well be an additional cause of the non satisfactory long-term results of conservative treatment which--in our view--mainly aim at bridging optimally the period of late neonatal presentation until liver transplantation in patients with CPS and OTC deficiency (except for mild forms).
为了做出医疗决策和提供咨询,需要对尿素循环障碍(UCD)患者的长期预后进行评估。我们自己的数据比较了采用仅限于蛋白质限制的旧疗法(即接近自然病史)的UCD患者与采用现代保守疗法的患者的预后,结果表明,生存率的提高是以更多存活的智力发育迟缓患者为代价的。我们讨论了那些罕见的遗传性疾病长期预后研究中可能存在的偏差,在这些疾病中,导致分解代谢危机的不可预测的环境因素对预后有着至关重要的影响。讨论了将峰值或初始氨值与昏迷持续时间相结合作为残疾预后的标准。在一些已发表的方案中,苯丁酸盐治疗会使支链氨基酸缺乏的饮食补偿被忽视,这很可能是保守治疗长期效果不理想的另一个原因,在我们看来,保守治疗主要旨在最佳地衔接晚期新生儿期直至患有CPS和OTC缺乏症(轻度形式除外)的患者进行肝移植的这段时间。